CYTK Q2 2024 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$249,000-71.3% YoY

Gross Profit

-$79M-31866.7% margin

Operating Income

-$130M-52277.9% margin

Net Income

-$143M-57557.4% margin

EPS (Diluted)

$-1.31

QoQ Revenue Growth

-70.2%

Cash Flow

Operating Cash Flow

-$99M

Free Cash Flow

-$101M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$1.4B

Stockholders' Equity

$109M

Cash & Equivalents

$191M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$249,000	$867,000	-71.3%
Gross Profit	-$79M	-$82M	+3.6%
Operating Income	-$130M	-$122M	-6.7%
Net Income	-$143M	-$129M	-11.4%

Revenue Segments

Research And Development

$249,000100%